Several clinical trials have showcased the remarkable cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in both DM and non-DM patients suffering from heart failure. This evidence concerns the gene SLC5A2 and diabetes mellitus.